Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Supportive and palliative care

3903 - Pooled analysis of treatment-related hypothyroidism with anti-PD-1/PD-L1 therapies in cancer patients


08 Oct 2016


Supportive and palliative care


Shaodong Hong


Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390


S. Hong, W. Fang, L. Zhang

Author affiliations

  • State Key Laboratory Of Oncology In South China, Sun Yat-sen University Cancer Center, 510060 - Guangzhou/CN


Abstract 3903


Blockade of programmed death 1 (PD-1), or its ligand, PD-L1, could restore T-cell immunity. Anti-PD-1/ or anti-PD-L1 antibodies have demonstrated promising efficacy in the treatment of cancer patients. The toxicity spectrum of PD-1/PD-L1 blockers is distinct from chemotherapy or other target agents. This study aims to investigate the overall incidence of treatment-related hypothyroidism with anti-PD-1/PD-L1 therapies in cancer patients.


A systematic search of literature up to January 2016 was performed in EDLINE, EMBASE, and Cochrane databases to identify relevant clinical trials. Paired reviewers independently selected articles for inclusion and extracted data. Pooled incidence was calculated using Comprehensive Meta-analysis using fixed or random effects model depending the heterogeneity of the included studies.


A total of 23 clinical trials with 5290 patients were included. The overall incidence of all- and high-grade hypothyroidism in cancer patients receiving anti-PD-1/PD-L1 therapies were 7.3% (95% CI, 5.9% to 9.1%) and 0.4% (95% CI, 0.2% to 0.7%), respectively. Adding anti-CTLA-4 antibodies to PD-1/PD-L1 blockers led to increased incidence of all-grade fatigue (16.4% vs. 6.4%, p 


Hypothyroidism is commonly seen with anti-PD-1/PD-L1 therapies in cancer patients. Early and appropriate management is required to avoid unnecessary dose reductions and transitory or definitive treatment discontinuations.

Clinical trial identification

Legal entity responsible for the study

Sun Yat-sen University Cancer Center


National Natural Science Funds of China (Grant No: 81372502)


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings